Table 3.
Objective indexes for the two groups
| Group 1 (n=36) | Group 2 (n=42) | P | |
|---|---|---|---|
| Penile length change (cm), mean±s.d. (range) | 0.4±0.9 (−1.6–1.8) | −0.8±0.7 (−2.3–0.8) | 0.00* |
| Testosterone (nmol l−1), mean±s.d. (range) | |||
| Before treatment | 10.3±3.4 (5.5–17.7) | 11.2±4.3 (4.6–22.5) | 0.34 |
| After treatment | 18.2±3.6 (11.1–25.6) | 16.0±4.0 (10.1–26.1) | 0.01* |
| NPT testing | |||
| Event number before treatment, mean±s.d. (range) | 2.9±2.3 (0–10.0) | 2.6±2.0 (0–7.0) | 0.48 |
| Event number after treatment, mean±s.d. (range) | 3.1±1.7 (0–7.0) | 3.0±1.6 (0–6.0) | 0.66 |
| Event duration before treatment (min), mean±s.d. (range) | 6.8±4.1 (0–17.0) | 7.1±4.1 (0–17.0) | 0.80 |
| Event duration after treatment (min), mean±s.d. (range) | 12.3±4.2 (5.0–20.0) | 13.0±4.8 (6.0–24.0) | 0.44 |
| Event rigidity before treatment (%), mean±s.d. (range) | 17.7±10.7 (0–41.0) | 18.3±12.2 (0–45.0) | 0.81 |
| Event rigidity after treatment (%), mean±s.d. (range) | 29.2±11.2 (8.0–55.0) | 25.0±10.2 (6.0–45.0) | 0.09 |
*P<0.05 indicates statistical significance. s.d.: standard deviation; ED: erectile dysfunction; NPT: nocturnal penile tumescence